Hong Kong Approval Expands Mainlanders’ Access to mRNA Covid Shots

Two messenger RNA-based Covid-19 vaccines developed by Germany’s BioNTech were officially registered in Hong Kong as regularly available treatments in the city, elevating the shots’ previous emergency-use approval.

The registration means the vaccines will be accessible to nonresidents of Hong Kong, including visitors from the mainland and other countries, medical professionals in the city told Caixin.